Navigation Links
Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:4/29/2013

BASKING RIDGE, N.J., April 29, 2013 /PRNewswire/ -- Regado Biosciences, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock.  The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Cowen & Company, LLC and BMO Capital Markets will act as joint book-running managers for the offering.  Canaccord Genuity Inc., Needham & Company, LLC , and Wedbush PacGrow Life Sciences will act as co-managers.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective.  These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus.  Copies of the preliminary prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140; or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. The actively controllable product candidates have the potential to improve outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at www.regadobio.com

Contacts:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm , Ph.D./Andrew Mielach 
jdrumm@tiberend.com; (212) 375-2664 
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
2. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
3. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
4. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
5. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
6. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
7. TNI BioTech Files Form 10 with SEC
8. Marrone Bio Innovations Files Patent for a Unique Bacillus Species
9. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
10. NDIS Approval of the Promega PowerPlex(R) Y23 System Enables More Usable Profiles in Less Time
11. Lucintel Profiles Top Five Global Polypropylene Companies: APAC is Expected to Drive Future Industry Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... September 01, 2020 , ... Slone Partners , ... announced the placement of Julianne Averill , CPA, as Chief Financial Officer ... operations and implementing key business strategies to accelerate Alveo’s growth as the company ...
(Date:8/15/2020)... ... 13, 2020 , ... Inc. magazine today revealed that Skysis ... of the nation’s fastest-growing private companies. The list represents a unique look at ... businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names gained ...
(Date:8/12/2020)... ... 12, 2020 , ... Inc. magazine today revealed that ... compliance consulting has been named on its annual Inc. 5000 list, the most ... look at the most successful companies within the American economy’s most dynamic segment—its ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... Introducing Ardent ... for transformative growth, , Known as MediVet Biologics since its ... , The new Ardent Animal Health will build on its base of ...
Breaking Biology Technology:
(Date:8/23/2020)... ... August 21, 2020 , ... ... has been published and is now available on the company’s global website. ... the X-ray analysis community, presenting current news and crystallographic research. , The ...
(Date:8/21/2020)... ... , ... The 19th Annual Bio-IT World Conference & ... and IT leaders goes VIRTUAL and announces its updated event features and full ... the leadership role of keeping our life science community connected by bringing you ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently announced ... for public health agencies of all sizes. With a focus on tracking symptoms ... find appropriate health care, Mosio helps public health departments automate communications and provide ...
Breaking Biology News(10 mins):